California research institutes, universities, and biopharmaceutical companies are a critical source of innovation, contributing to the development of approximately a quarter of new drugs that the U.S. Food and Drug Administration approved last year. But despite the breakthroughs, more mundane issues of tariffs, drug pricing, and access to funding continue to weigh on leaders within the sector. We spoke to Tim Scott, president and CEO of Biocom California, about the current state of the biotech industry, a surge in mergers and acquisitions driven by the looming patent cliff, and what Biocom is doing to support companies through partnerships, advocacy, and policy reform.
All content for The Big4Bio Podcast is the property of Big4Bio and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
California research institutes, universities, and biopharmaceutical companies are a critical source of innovation, contributing to the development of approximately a quarter of new drugs that the U.S. Food and Drug Administration approved last year. But despite the breakthroughs, more mundane issues of tariffs, drug pricing, and access to funding continue to weigh on leaders within the sector. We spoke to Tim Scott, president and CEO of Biocom California, about the current state of the biotech industry, a surge in mergers and acquisitions driven by the looming patent cliff, and what Biocom is doing to support companies through partnerships, advocacy, and policy reform.
AI is increasingly being integrated into the drug discovery process and promises to not only increase efficiency, but expand the chemical space for drug developers to explore. Even though it is still early days for the technology, it is already demonstrating its ability to be a powerful tool across a broad set of applications from testing molecules in silico to designing new molecular entities. We spoke to David Clark, Senior Research Leader in UK Small Molecule Drug Discovery at Charles River Laboratories, about the potential to harness the predictive powers of AI to improve drug discovery, how generative AI can get us to better drugs faster and cheaper, and how this technology is reshaping the drug discovery process.
The Big4Bio Podcast
California research institutes, universities, and biopharmaceutical companies are a critical source of innovation, contributing to the development of approximately a quarter of new drugs that the U.S. Food and Drug Administration approved last year. But despite the breakthroughs, more mundane issues of tariffs, drug pricing, and access to funding continue to weigh on leaders within the sector. We spoke to Tim Scott, president and CEO of Biocom California, about the current state of the biotech industry, a surge in mergers and acquisitions driven by the looming patent cliff, and what Biocom is doing to support companies through partnerships, advocacy, and policy reform.
